top of page

Lyell Immunopharma's CEO on the future of TIL and CAR-T therapies for solid tumor targets

On the heels of a historic recent approval for the class, Lynn Seely describes the science behind TIL therapies and how Lyell is manufacturing its products to improve potency. Plus, a discussion on ROR1 as a solid tumor target for CAR-T.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page